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 Structure-Activity Relationship of 2-arylquinazolin-4-ones as tankyrase inhibitors 
 8-Methyl group gives selectivity for tankyrases over PARP-1 and PARP-2 
 Polar groups at the 8-position give poor isoform-selectivity 
 Crystal structures rationalised the observed selectivity 
 Reveal a novel, potent and selective tankyrase and Wnt signalling inhibitor 
Abstract 
Tankyrases (TNKSs), members of the PARP (Poly(ADP-ribose)polymerases) superfamily of 
enzymes, have gained interest as therapeutic drug targets, especially as they are involved in the 
regulation of Wnt signalling. A series of 2-arylquinazolin-4-ones with varying substituents at 
the 8-position was synthesised. An 8-methyl group (compared to 8-H, 8-OMe, 8-OH), together 
with a 4’-hydrophobic or electron-withdrawing group, provided the most potency and 
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selectivity towards TNKSs. Co-crystal structures of selected compounds with TNKS-2 
revealed that the protein around the 8-position is more hydrophobic in TNKS-2 compared to 
PARP-1/2, rationalising the selectivity. The NAD+-binding site contains a hydrophobic cavity 
which accommodates the 2-aryl group; in TNKS-2, this has a tunnel to the exterior but the 
cavity is closed in PARP-1. 8-Methyl-2-(4-trifluoromethylphenyl)quinazolin-4-one was 
identified as a potent and selective inhibitor of TNKSs and Wnt signalling. This compound and 
analogues could serve as molecular probes to study proliferative signalling and for 
development of inhibitors of TNKSs as drugs. 
1. Introduction 
Tankyrases (TNKSs) are members of the poly(ADP-ribose)polymerase (PARP) family of 
enzymes responsible for poly(ADP-ribosyl)ating acceptor proteins, using NAD+ as a substrate 
[1]. TNKS-1 (PARP-5a, ARTD5) was first reported in 1998, being located at telomeres [2]. A 
closely-related isoform, TNKS-2 (PARP-5b, ARTD6), was first reported in 2001 [3]. TNKS-
1 poly(ADP-ribosyl)ates telomere repeating binding factor (TRF1) and itself in order to 
regulate the elongation of telomeres [4-6]. TNKS-1 is essential for the correct structure and 
function of the mitotic spindle and centrosome through poly(ADP-ribosyl)ation of nuclear 
mitotic apparatus protein (NuMA) [7-9]. TNKS-1 is also involved in the glucose transport 
system [10,11]. It has a regulatory role in the life cycle of viruses, such as Epstein-Barr virus 
and Herpes simplex virus [12,13]. Aberrant Wnt signalling is found in the majority of colon 
cancers [14]. Tankyrase-1/2 is a component of the Wnt pathway, where it poly(ADP-
ribosyl)ates Axin [14]. Inhibition of TNKSs causes stabilisation of Axin and degradation of -
catenin, thus decreasing nuclear -catenin and inhibiting Wnt / -catenin-driven proliferation 
of cancer cells [14]. Increased nuclear accumulation of -catenin is found in many tumours 
[15-19] and inhibition of TNKS and Wnt signalling leads to antitumour activity in vivo [20,21]. 
Tankyrases are over-expressed in several clinical cancers and cancer cell lines, compared with 
the corresponding normal tissue / cell type. These tumours include breast cancer [4,22], colon 
cancer [23,24], chronic myeloid leukaemia [25], brain tumours [26,27], gastric cancers [28] 
and bladder cancers [29], pointing to one or more critical roles for the TNKSs in various tumour 
types. 
Two binding sub-sites within the NAD+-binding site have been identified and targeted for the 
design and evaluation of TNKS inhibitors. One sub-site normally binds the nicotinamide part 
of NAD+ using the classical PARP motif though H-bonding to Ser1068 and Gly1032 and -
stacking interactions with Tyr1071 (TNKS-2 numbering). Several of the known inhibitors of 
the TNKSs bind here, including flavones 1 [30], 3-arylisoquinolin-1-ones 2 [31] and aryltetra-
hydronaphthyridinones 3 (Figure 1) [32]. In addition, 2-arylquinazolin-4-one 4, containing a 
large and hydrophobic 4’-tertbutylphenyl group, binds with the same conformation as 1-3 and 
is a potent inhibitor of TNKSs [33]. These interactions are also seen for XAV939 5, an 
extensively studied early inhibitor of the TNKSs [34]. IWR-1 6 binds exclusively to the 
adenosine-binding site via induction of conformational change of specific amino-acid residues 
and does not interact with the nicotinamide-binding site [35]. IWR-1 6 has been used as a 
scaffold towards the design and evaluation of additional inhibitors that bind to the adenosine-
binding site, such as the oxazolidinone derivative 7 [36,37] and WIKI-4 8 [38]. There is 83% 
overall sequence homology between TNKS-1 and TNKS-2 and 94% sequence homology 
between TNKS-1 and TNKS-2 at the catalytic domain; structures of both domains have been 
solved. In many circumstances, these isoforms perform their biomolecular functions 
redundantly [39]. 
In a preliminary communication, we previously disclosed a set of 8-methyl-2-arylquinazolin-
4-ones 9 that bind to the nicotinamide-binding site [40]. The binding modes of these com-
pounds were rationalised using modelling in silico that indicated specific tolerances around the 
2-arylquinazolin-4-one scaffold. Compounds such as 4, 6 and 9 were used to design dual-
binding inhibitors that are capable of binding to the nicotinamide-binding site as well as inter-
acting with the adenosine-binding site; these include 10 and 11 [41,42]. Although our prelim-
inary study provided some initial information regarding Structure-Activity Relationships 
(SARs) of quinazolin-4-ones, to date, a comprehensive study into the SAR around the 4’- and 
8-positions of the quinazolin-4-one scaffold and correlation with inhibition of TNKSs has not 
been performed. Here, we report the evaluation of our extended library of 2-arylquinazolinones 
with various groups at the 8-position, as well as a detailed assessment of hydrophobic, hydro-
philic, electron-withdrawing, electron-neutral and electron-donating groups at the 4’-position. 
Counter-screening against PARP-1 and PARP-2 measured selectivity. Crystallographic studies 
rationalise the binding mode of these molecules, with particular attention to the nature of the 
8-substituent. They reveal that 4’-groups which are hydrophobic and / or electron-withdrawing 
(Me, Br, Cl, CF3) are optimal for potent and selective inhibition of the TNKSs compared to 
their activity against PARP-1 and PARP-2. To validate the activity of these novel compounds 
as inhibitors of potential active oncogenic Wnt signalling, a mouse embryonic stem cell 
(mESC) Wnt reporter assay was used. Our studies reveal that 8-methyl-2-(4-
trifluoromethylphenyl)quinazolin-4-one 18c is a potent and selective inhibitor of the TNKSs 
and Wnt signalling. 
2. Results and Discussion 
2.1. Chemical synthesis 
Building on our original preliminary communication [40], we set out to prepare an extensive 
library of compounds, using a rational drug design approach, to assess the correlations between 
varying the 4’-group carried on the 2-phenyl ring and substitutions at the -6, -7 and -8 positions 
of the quinazolin-4-one scaffold with inhibition of TNKSs. The synthesis of quinazolin-4-ones 
used classical methods. 8-Unsubstituted 2-arylquinazolin-4-ones 13a-g,i were synthesised in 
moderate yields using one-pot condensation of anthranilamide 12 with various 4-substituted 
Figure 1. Structures of 1-11, reported inhibitors of tankyrases. 
benzaldehyde derivatives, in the 
presence of hydrogensulfite ion, with in 
situ atmospheric oxidation of the 
intermediate aminal (Scheme 1). 
Reduction of the aromatic nitro group 
was achieved by transfer hydrogenation 
of 13g to provide the aniline 13h. The 4’-
methoxyphenyl group of 13i was 
demethylated to furnish the corres-
ponding phenol in 13j. In this series, the 
need for a lactam motif was tested with 
the simple amides 14. Acylation of 12 
with various 4-substituted benzoyl 
chlorides gave 14a-g,i. Transfer hydro-
genation of 14g gave the aniline 
contained in 14h but attempted selective 
demethylation of 14i failed. 
Treatment  of 15a,b with 1,1’-carbonyl-
diimidazole at elevated temperatures 
formed the intermediates (N-acyl-
imidazoles or isatoic anhydrides) which were treated with aqueous ammonia to give 16a,b in 
good yields. Carbodiimide (EDC) activation and subsequent treatment with aqueous ammonia 
also provided 16a,b in excellent yields [43,44]. The conversion of 16a to 17 and 18 has been 
briefly described previously [40]. Acylation of 3-methoxyanthranilamide 16b with 4-substit-
uted benzoyl chlorides provided 19a-g,i. The 4’-nitro group of 19g was reduced to the corres-
ponding amine using transfer hydrogenation conditions as before. Cyclisation of 19a-g,i under 
strongly basic aqueous conditions (NaOH) gave 20a-g,i in high yields. Dilute reaction mixtures 
and elevated temperatures were used to provide efficient cyclisation under basic conditions to 
the desired products. 
Scheme 1. Synthesis of 2-arylquinazolin-4-ones 13a-j 
and acylated anthranilamides 14a-i. Reagents and 
conditions: i, ArCHO, NaHCO3, AcNMe2, 150°C, open 
flask; ii, +NH4HCO2-, Pd/C, MeOH, DMF; iii, BBr3, 
CH2Cl2, reflux, then NaOH; iv, ArCOCl, pyridine, dry 
THF. 
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Scheme 2. Synthesis of 2-arylquinazolin-4-ones 18,20,21 with various 4’- and 8-substituents. Reagents and 
conditions: i, CDI or EDC, aq. NH3, DMF; ii, ArCOCl, pyridine, dry THF; iii, aq. NaOH (0.5 M), 60 °C; iv, 
+NH4HCO2-, Pd/C, MeOH, DMF; v, BBr3, CH2Cl2, reflux, then NaOH. 
Transfer hydrogenation was employed, 
as before, to reduce the nitro group of 20g to the aniline in 20h. Demethylation of 20a-g using 
BBr3 provided 21a-g in satisfactory yields. Transfer hydrogenation of the nitro group in 21g 
gave 21h. Simultaneous demethylation of the 8- and 4’-methoxy groups of 20i gave the 
corresponding diol 21j. 
Previous studies in silico suggested that substituents may not be tolerated at the 6- and 7-
positions of the quinazolinone core. To test this experimentally, we prepared 31 and 32, which 
are regioisomers of 18b. The 6,7,8-trimethoxyquinazolinone 33 was also a target in this part of 
the study to assess whether a trisubstituted quinazolin-4-one would retain significant inhibitory 
activity towards the TNKSs. Briefly, formation of the primary amides from anthranilic acids 
22-24 via EDC activation and treatment with aqueous ammonia gave 25-27. Compounds 25,26 
were acylated with 4-methylbenzoyl chloride to give the amides 28,29. Amide 27 was acylated 
with benzoyl chloride to give 30, after which 28-30 were cyclised under the usual aqueous 
basic conditions to provide 31-33. 
 
Scheme 3. Synthesis of 6- and 7-substituted 2-arylquinaz-
olin-4-ones 31-33. Reagents and conditions: i, CDI, aq. 
NH3; ii, ArCOCl, pyridine, dry THF; iii, aq. NaOH 
(0.5 M). 
Compound 39, which contains a CH2NHCbz 
extension at the 4’-position, was shown in our 
preliminary study to retain good inhibitory 
activity against both TNKSs [40]. The 
extension is predicted by studies in silico to 
extend through the tunnel from the hydrophobic 
cavity to the exterior, where the aromatic ring 
of the Cbz may interact with the adenosine-
binding site. To evaluate whether the presence 
of a 8-methyl substituent on the quinazolinone 
makes a significant contribution to binding in 
the presence of the CH2NHCbz 4’-extension, 
analogue 38, lacking the 8-Me group, was 
prepared along with the related 6,7,8-tri-
methoxy derivative 40 (Scheme 4). 4-
(Aminomethyl)benzoic acid 34 was acylated 
with benzyl chloroformate under Schotten-
Baumann conditions [45] before formation of the acid chloride. Subsequent coupling with anth-
ranilamides 12, 16a, 27 gave 35-37, respectively. Attempted cyclisation of 35-37 with aqueous 
sodium hydroxide led to hydrolysis of the carbamate; therefore, milder, less nucleophilic, basic 
conditions (aq. K2CO3) gave 38-40. The Cbz units were removed by treatment with HBr, 
revealing the respective primary amines 41-43 as their hydrobromide salts, to test the 
tolerability of a polar charged moiety in the tunnel. 
 Replacement of a benzene ring with 
thiophene is often considered as a 
conservative manipulation in drug 
design. This replacement was tested in 
the current series by synthesising and 
evaluating the thienopyrimidinone 45. 
We have previously reported the 
synthesis of 45 in seven steps from 
dimethyl 3-thiahexanedioate in 3.5% 
overall yield [46]. With the new com-
mercial availability of the aminothio-
phenecarboxamide 44, we were able to 
prepare 45 in one step (Scheme 5). A 
Cu-catalysed displacement of the 
bromine with benzylamine, with oxidat-
ive cyclisation in situ, afforded the target 
in 16% yield. The ferrocene derivative 
47 was assembled to evaluate the 
possibility of accommodating three-
dimensional bulk into the hydrophobic 
pocket of TNKSs. Compound 47 was 
prepared in the usual way (Scheme 5) by 
acylation of anthranilamide 12 with 
ferrocenecarbonyl chloride, followed by 
cyclisation of intermediate 46 with 
under aqueous basic conditions. 
Scheme 5. Synthesis of thienopyrimidinone 45 
and ferrocenylquinazolin-4-one 47. Reagents 
and conditions: i, K2CO3, CuBr, BnNH2, 
125°C, DMSO, open flask; ii, 
ferrocenecarbonyl chloride, pyridine, dry THF; 
iii, aq. NaOH (0.5 M), 100°C. 
Scheme 4. Synthesis of 2-arylquinazolin-4-ones 38-
43 with extensions at the 4’-position. Reagents and 
conditions: i, CbzCl, aq. K2CO3; ii, SOCl2, iii, 12 or 
16a or 27, pyridine, dry THF; iv, aq. K2CO3 (1.0 M), 
100°C; v, HBr, AcOH. 
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2.2. Potency and selectivity of inhibition of tankyrases 
An initial screen of the inhibitory activity of all test compounds was performed using three 
different concentrations of inhibitor using our previously developed assay, which uses an imm-
obilised construct of the catalytic and SAM domains of TNKS-2 [40]. Values are expressed as 
percentage inhibition of enzyme activity relative to control containing no inhibitor (see Supp-
lementary Information). From this initial screen, compounds that diminished enzyme activity 
by >60% at 1.0 µM were evaluated further to determine IC50 values against TNKS-1, TNKS-
2 and, for counter-screening, PARP-1. Compounds that showed good selectivity of inhibition 
of TNKSs, compared to PARP-1, were also assessed against PARP-2. 
Benzamides 14a-i, 17a-h, 19a-h, 35 and 36 were evaluated against TNKS-2 at 1.0 µM, 100 
nM and 10 nM (Supplementary Information) to assess the importance of the lactam and its 
constraint of the conformation of the H-bond motif, which makes interactions with Glu1138 
and Ser1068 [32]. 1H NMR data suggest that the primary amide in these compounds is coplanar 
with the benzene ring but rotated 180 
relative to its conformation in the quinazol-
inones (Figure 2). Compounds 14a-i, 17a-
h, 19a-h, 35 and 36 displayed poor 
inhibition towards TNKS-2 at 1.0 µM and, 
therefore, were not evaluated further. It is 
thus important that the lactam ring is fixed 
to potentiate inhibitory activity towards 
TNKSs. 
Figure 2. Conformations of aroylanthranilamides 48 
and 2-arylquinazolinones 49 in solution. 
Table 1. Inhibition of TNKS-1, TNKS-2, PARP-1 and PARP-2 by 8-H 2-arylquinazolin-4-ones 13. IC50 values 
in nM. 
 
Cpd.  R4‘ TNKS-1 TNKS-2 PARP-1 PARP-2 
XAV939 5  10 ± 3 17 ± 6 1200 ± 23  
13a H 1406 ± 156 2200 ± 32 2863 ± 1753  
13b Me 346 ± 25 540 ± 195 424 ± 215  
13c CF3 425 ± 177 133 ± 82 >100000a >10000a 
13d Cl 485 ± 50 54 ± 4 >100000a 2600 ± 124 
13e Br 224 ± 49 101 ± 29 >100000a >100000a 
13f F 781 ± 125 1102 ± 95 >100000a 4688 ± 918 
13g NO2 1100 ± 49 259 ± 125 >10000a 2064 ± 108 
13h NH2 786 ± 162 690 ± 160 1295 ± 121  
13i OMe 250 ± 70 611 ± 125 2718 ± 1846  
13j OH 528 ± 76 189 ± 50 6429 ± 769  
38 CH2NHCbz 2423 ± 1825  45 ± 24 >10000a >10000a 
a Limited by solubility. 
 
 The 2-arylquinazolin-4-one derivative 31, bearing a methyl group at the 7-position, showed 
weak inhibition against TNKS-2 (18% at 1.0 µM; see Supplementary Information). Compound 
32 bearing a 6-methyl group also displayed weak inhibition of TNKS-2 (10% at 1.0 µM). 
Previous studies in silico, accompanied by analysis of the TNKS-2–5 bioactive conformation 
(PDB code 3KR8), revealed that substituents in the 7- or 6-positions may be tolerated via 
potential interaction with Glu1138 but the hydrophobic Me would not allow this. 
In our preliminary communication, we reported that a charged primary amine was not tolerated 
at the junction of the hydro-phobic cavity and the tunnel, in that 42 (carrying 4’-CH2N+H3) was 
much less active as an inhibitor of TNKS-2 than was the corresponding 4’-Me compound 18b 
[40]. By contrast, more lipophilic charged tertiary amines are tolerated in this position in the 
3-arylisoquinolin-1-one series [31]. The deleterious effect of the charged polar 4’-CH2N+H3 in 
the present 2-arylquinazolin-4-one series was confirmed by the minimal inhibition of TNKS-2 
by the 8-H analogue 41 at 1.0 M and by the complete inactivity of 43 at this concentration. 
The data for inhibition of the enzymes by the 8-H quinazolinones 13a-j are shown in Table 1. 
In this series, compounds 13c (4’-CF3), 13d (4’-Cl) and 13e (4’-Br), which carry lipophilic 
groups on the 2-phenyl ring, demonstrate good inhibition of TNKS-1 and TNKS-2; good 
isoform-selectivity was noted, with only weak activity against PARP-1 and PARP-2. 
Curiously, the 4’-Me analogue 13b showed no isoform-selectivity whatsoever, being a good 
inhibitor of PARP-1 (IC50 = 424 nM). Slightly weaker activity against the tankyrases was 
demonstrated by 13h-j, which carry hydrophilic and / or electron-donating substituents at the 
4’-position; these compounds also showed some inhibition of PARP-1, leading to lower 
selectivity than 13c-e. Small substituents (H, F) at the 4’-position in 13a,f lead to lower activity 
against the tankyrases and greater affinity for  PARP-1. The planar –M nitro group in 13g gives 
weaker activity against TNKS-1 but increased affinity for PARP-2, giving lower selectivity. In 
Table 2. Inhibition of TNKS-1, TNKS-2, PARP-1 and PARP-2 by 8-OMe 2-arylquinazolin-4-ones 20. IC50 
values in nM. 
 
Cpd.  R4‘ TNKS-1 TNKS-2 PARP-1 PARP-2 
20a H 475 ± 12 1029 ± 235 >10000a 1539 ± 238 
20b Me 153 ± 12 167 ± 60 2404 ± 575  
20c CF3 73 ± 2 87 ± 34 >100000a 570 ± 25 
20d Cl 155 ± 55 62 ± 11 >10000a 6022 ± 1107 
20e Br 111 ± 5 106 ± 23 >100000a 259 ± 84 
20f F 299 ± 74 459 ± 166 >10000a 1562 ± 85 
20g NO2 873 ± 334 863 ± 221 >10000a 928 ± 46 
20h NH2 1284 ± 234 1076 ± 158 1589 ± 114  
20i OMe 346 ± 25 128 ± 27 1244 ± 29  
a Limited by solubility. 
 
this 8-H quinazolinone series, optimum 
activity and selectivity is seen for non-
polar units at the 4’-position. However, 
the extended –CH2NHCbz at the 4’-
position in 38 provided remarkable 
selectivity for the TNKS-2 isoform over 
TNKS-1, PARP-1 and PARP-2.  
Changing the 8-substituent from 8-H to 
8-OMe (Table 2 20a-i) provided an over-
all increase of potency of inhibition of 
tankyrases, compared to 13a-j. The 
nature of the 4’-group for compounds 
20a-i shows similar SAR as for 13a-j. 
Large and electron-withdrawing groups 
(20c-g) provide potent and selective 
inhibition of TNKS. Again, in this series 
(Table 2), selective inhibition of TNKS is 
observed with small electron-with-
drawing 4’-groups (4’-F in 20f) then 
small neutral groups (4’-H in 20a), when 
comparing inhibition values against those 
for PARP-1. However, in this series, the 
presence of an electron-donating 8-OMe 
group provides a notable increase in inhibitory potency against PARP-2. For example, 20c,e,g 
show sub-micromolar inhibition of PARP-2, giving poor selectivity of inhibition of the target 
tankyrases. However, these compounds may represent a new starting-point for the design of 
PARP-2-selective inhibitors, with 20e showing >300-fold selectivity for PARP-2 over PARP-
1. It is notable that previously reported selective inhibitors of PARP-2 were claimed to have 
selectivity of only ca. 50-fold (for 5-benzoyloxyisoquinolin-1-one) [48], which could not be 
repeated by other workers who demonstrated ca. 11-fold selectivity for the optimum compound 
5-benzamidoisoquinolin-1-one in a comparative study [49,50]. 
The presence of an electron-donating / hydrophilic 8-OH group (21a-i, Table 3) provides more 
potency towards TNKS, compared to 13a-j (8-H), whereas the IC50 values are broadly similar 
to those for 20a-i (8-OMe). However, the introduction of this polar group in 13a-j significantly 
enhances binding to PARP-1, leading to lower selectivity. As inhibitors 21a-i showed poor 
selectivity vs. PARP-1, they were not evaluated further against PARP-2. In this series, large 
(Cl, Br) and electron-withdrawing groups (F, CF3, NO2) provided more potent inhibition of 
TNKSs, compared to those bearing small 4’-substituents, an observation that mirrors those 
observed for compounds presented in Tables 1 and 2. Interestingly, compound 21, presenting 
an 8-OH substituent, had much greater antiproliferative activity against HT29 human colon 
carcinoma cells (see Supplementary Information), compared to all other quinazolin-4-ones 
examined. One may speculate whether a requirement for concurrent inhibition of TNKSs and 
PARP-1 may be required to achieve this activity in HT29 colon cancer cells or that the 
compounds may be taken up into the cells more effectively. However, the observation that the 
8-Me compound 18c is capable of inhibiting Wnt signalling in cells (see below) suggests that 
this series can be taken up into cells readily. 
Table 3. Inhibition of TNKS-1, TNKS-2, PARP-1 and 
PARP-2 by 8-OH 2-arylquinazolin-4-ones 21. IC50 values 
in nM. 
 
Cpd.  R4‘ TNKS-1 TNKS-2 PARP-1 
21a H 195 ± 21 180 ± 94 1034 ± 116 
21b Me 22 ± 2 44 ± 6 559 ± 34 
21c CF3 53 ± 11 25 ± 1 3105 ± 172 
21d Cl 46 ± 12 49 ± 14 645 ± 221 
21e Br 47 ± 3 15 ± 1 130 ± 40 
21f F 101 ± 39 263 ± 134 1361 ± 608 
21g NO2 58 ± 23 191 ± 52 105 ± 5 
21h NH2 83 ± 18 219 ± 51 289 ± 135 
21j OH 156 ± 28 86 ± 10 856 ± 137 
a Limited by solubility. 
 
The inhibitory activities of 18a-j, 39 and 42 (8-Me, Table 4) against TNKS-1, TNKS-2 and 
PARP-1 were reported in our preliminary communication [40] and are provided for 
comparison. Compounds that did not display PARP-1 inhibitory activity up to 5000 nM have 
now been further assessed for PARP-2 inhibition to assess their isoform-selectivity further. 
Inhibition of PARP-2 by these compounds was broadly similar to inhibition of PARP-1 but 
with somewhat lower IC50 values. The excellent isoform selectivity for TNKSs vs. other PARPs 
is further confirmed. 
The quinazolinone core was changed to thieno[3,4-d]pyrimidin-4(3H)-one in 45. The 7-posit-
ion of 45 is unsubstituted, so comparison with 13a is apposite. The activities of 45 against the 
isoforms are slightly greater (IC50 vs. TNKS-1 = 466 ± 11 nM, IC50 vs. TNKS-2 = 2455 ± 123 
nM, IC50 vs. PARP-1 = >10000 nM, IC50 vs. PARP-2 = 11500 ± 225 nM), reflecting the con-
servatism of the benzene-to-thiophene replacement. However, 45 is much less potent than 
XAV939 5 against the tankyrases (Table 1), showing the importance of the flexibility of the 
tetrahydrothiapyran in 5. The ferrocenylquinazolin-4-one 47 displayed weak inhibition of the 
TNKSs (IC50 vs.TNKS-1 = 1217 ± 28 nM , IC50 vs. TNKS-2 = 4589 ± 966 nM); weaker binding 
to PARP-1 was noted (IC50 >10 M) but PARP-2 was inhibited with IC50 = 1600 ± 114 nM). 
Similar activity has been reported previously by us for 3-ferrocenyl-5-methylisoquinolin-1-one 
[31]. These data show that the hydrophobic pocket in the tankyrases is capable of accepting 
some 3-D bulk. 
Table 4. Inhibition of TNKS-1, TNKS-2, PARP-1 and PARP-2 by 8-OH 2-arylquinazolin-4-ones 18. IC50 
values in nM. 
 
Cpd.  R4‘ TNKS-1 TNKS-2 PARP-1 PARP-2 
18a H 41 ± 18a 42 ± 18a 795 ± 48a  
18b Me 35 ± 12a 7 ± 2a 685 ± 89a  
18c CF3 48 ± 7a 10 ± 3a >5000a,b 3098 ± 1524 
18d Cl 36 ± 4a 33 ± 7a >5000a,b 6350 ± 704 
18e Br 32 ± 4a 6 ± 1a >5000a,b 10529 ± 3322 
18f F 44 ± 13a 40 ± 8a >5000a,b 683 ± 15 
18g NO2 32 ± 8a 30 ± 14a 104 ± 46a  
18h NH2 35 ± 10a 3 ± 1a 504 ± 128a  
18i OMe 37 ± 7a 12 ± 4a 891 ± 142a  
18j OH 52 ± 11a 6 ± 1a 1200 ± 160a  
39 CH2NHCbz 44 ± 4a 73 ± 28a >5000a,b >100000b 
42 CH2N+H3 Br- 907 ± 26 43 ± 13 266 ± 19  
a Determined previously [40]. b Limited by solubility. 
Several SAR themes are evident from this comprehensive study. Firstly, the hydrophobic 8-
Me group provides increased potency, compared to 8-H, 8-OMe and 8-OH, regardless of the 
nature of the 4’-substituent. The SAR at the 4’-substituent for the 8-Me in 18a-j is comparable 
to those in this region in 13a-j, 20a-i and 21a-h,j, where large and electron-withdrawing 4’-
groups are required for potent TNKS inhibition. Again, small 4’-electron-withdrawing groups 
(4’-F in 18f) provides similar potency against TNKSs as compounds bearing small 4’-neutral 
groups (4’-H in 18a). However, as with 13f, 20f and 21f (all 4’-F), 18f provides selective 
inhibition of TNKSs compared to their respective 4’-H counterparts. Compound 18e, 
containing a large 4’-Br, is the most potent and selective TNKS inhibitor in this series. The 4’-
extended Cbz group of 39 retains selective inhibition towards TNKSs over PARP-1/-2. 
2.3. Structural studies 
To rationalise SARs displayed in Tables 1-4, selected compounds were co-crystallised with the 
catalytic domain of TNKS-2. The structures of nine compounds (13b, 13c, 18b, 18c, 20b, 20c, 
21b, 21c and 38) in complex with this construct were solved at 1.7 to 2.4 Å resolution (Figure 
3), varying the 8-substituent but maintaining the 4’-group as either 4’-methyl (13b, 18b, 20b, 
21b) or 4’-trifluoromethyl (13c, 18c, 20c, 21c). In all cases, the quinazolin-4-one scaffold binds 
into the nicotinamide-binding site forming the usual conserved interactions. The lactam N-H 
forms a hydrogen bond to the backbone carbonyl of Gly1032, whilst the C=O of the lactam forms 
two hydrogen bonds to the backbone C=O of Gly1032 and the hydroxy side chain of Ser1068. The 
quinazolinone / lactam ring creates -stacking interactions with Tyr1071. The hydrophobic 
cavity, lined with Tyr1050, Ile1075, Pro1034 and Phe1035, can accommodate large groups at the 4’-
position, including Br (13e, 18e, 20e and 21e) and Cl (13d, 18d, 20d and 21d). Compound 38, 
which contains the extended 4’-CH2NHCO2CH2Ph interacts further with Pro1034 and Phe1035, 
unlike the simpler quinazolinones. The binding of 38 does not cause large changes in the 
conformation of the protein (Figure 3 panel I) but there is some minor structural movement of 
the side-chain of Ile1075 as the backbone amide NH of Ile1075 makes a partial hydrogen bond 
(3.71 Å; not shown for clarity) to the benzyl oxygen of 38. No additional or significant 
movement is observed for residues that are in close proximity to the large 4’-CH2NHCbz group 
of 38 as it threads treads through the tunnel at the distal end of the hydrophobic cavity. 
Selective inhibition of TNKSs over PARP-1 can be rationalised by structural alignment of the 
TNKS-2-38 structure with a PARP-1 structure containing 8-hydroxy-2-methylquinazolin-4-
one (PDB code 4PAX) (Figure 3, panel J). The two protein structures were aligned to overlap 
the nicotinamide-binding motifs and the structure of the ligand 8-hydroxy-2-methylquinazolin-
4-one has been removed for clarity in the figures. Figure 3, panel J shows that the 2-aryl unit 
of 38 would cause steric clashes with a-helical residues Asn767, Asp766 and Gln763 of PARP-1. 
Additionally, the cavity accommodating the 4’-carboxybenzyl group is in a closed state in 
PARP-1, whereas the corresponding region of protein in TNKS-2 is hydrophobic and open to 
solvent through the tunnel (Figure 3, panel I). The hydrophilic nature of this PARP-1 surface 
is, therefore, suited towards 2-arylquinazolin-4-one derivatives containing hydrophilic 4’-
substituents (4’-NH2 and 4’-OH). Conversely, this hydrophilic -helical region in PARP-1 is 
intolerant of electronegative or large hydrophobic groups at the 4’-position, leading to greater 
selectivity of 2-arylquinazolinones carrying 4’-hydrophobic groups towards TNKS-1 and 
TNKS-2. The presence of a large, hydrophobic 4’-group causing potent TNKS inhibition has 
been observed using 4 [33]. A clear SAR at the 8-position was observed for inhibition of both 
TNKS-1 and TNKS-2: 8-Me > 8-OH > 8-OMe > 8-H. Similar SAR had been deduced earlier 
for the 3-arylisoquinolin-1-ones (5-Me > 5-OMe > 5-OH = 5-NH2 = 5-F). Structural alignment 
of the PARP-1 (PDB code 4PAX) and TNKS-2-38 crystal structures shows that a larger space 
around the 8-position is present in PARP-1 than in TNKS-2 (Figure 3). In addition, the corresp-
onding hydrophobic residue Tyr1050 of TNKS-2 is absent from PARP-1. Glu988 in PARP-1 is 3 
Å closer to the 8-position than the corresponding Glu1138 of TNKS-2. The closer proximity of 
Figure 3. Crystal structures of Panel A 13b, Panel B 13c, Panel C 20b, Panel D 20c, Panel E 21b, Panel F 21c, 
Panel G 18b, Panel H 18c, Panel I 38 bound to TNKS-2. Overlay of 38 onto PARP-1 (panel J). Key residues 
are in purple and key H-bond interactions are shown as dashed lines. 
Glu988 and lack of a hydrophobic residue 
around the 8-position of the quinazolinone 
scaffold provides a more hydrophilic site in 
PARP-1, compared to TNKS-2, and may 
possibly explain why hydrophilic groups in 
the 8-position (such as 8-OH) is well toler-
ated in the PARP-1 binding site. The protein 
surrounding the 8-position of the 
quinazolinone scaffold in TNKS-2 is more 
hydrophobic in nature due to the presence of 
a proximal Tyr1050 and, therefore, a 
hydrophobic 8-Me group in 18a-j provides 
improved inhibitory activity and selectivity 
towards TNKSs. 
The TNKS-2 structure was solved with two 
molecules in the unit cell and, therefore, the 
numbers of water molecules in close 
proximity to the quinazolinone 8-position in 
both monomer chains A and B were consid-
ered. The number of water molecules in this 
area was averaged between the two chains. 
We measured the number and distance of 
water molecules that were within 6.5 Å of the 
8-carbon of the quinazolinone scaffold for 
compounds 4b, 10b, 11b and 12b. There 
appears to be correlation between the amount 
and distance of water molecules and 
inhibitory activity of these compounds. This 
is particularly seen between compounds 4b 
and 10b. The presence of a total of six water 
molecules (three in each chain) for 4b results in a ten-fold decrease in inhibitory activity, 
compared with 10b which contains four water molecules (two in each chain) that are in 
proximity to C-8 of the compound. A combination of the hydrophobic nature of protein 
surrounding the 8-position in TNKS-1 and TNKS-2 (compared to PARP-1 which is more 
hydrophilic) and the amount of water repulsion in this region may provide an explanation why 
8-Me is optimum for potency against TNKSs. 
Most of the quinazolinones reported here were more potent towards PARP-2 than against 
PARP-1. XAV939 5, which also binds to the nicotinamide-binding site, was eight-fold more 
potent towards PARP-2 compared to PARP-1, which was consistent with literature values [33]. 
2.4. Inhibition of Wnt signalling 
Inhibitors 5, 18c, 18d, 18e, 18f, 20d, 20c and 39 displayed selective and potent TNKS 
inhibition and were investigated further to assess their cellular activity as inhibitors of the Wnt 
signalling cascade, using an established assay based on mouse embryonic stem cells (mESCs) 
[51,52]. In mESCs, canonical Wnt signalling is negligible and only becomes active as the cells 
differentiate [51,53,54]. As shown in Figure 4 (grey) and Table 5, E14Tg2A mESCs, which 
lack the green fluorescent protein (GFP) gene, showed minimal fluorescence. Derived TLg2 
Figure 4. Flow-cytometric analysis of TLg2 cells 
(and E14Tg2A control cells) grown under the 
indicated culture conditions. The black line indic-
ates the median GFP fluorescence intensity of TLg2 
cells cultured for 3 d in the presence of N2B27 
medium and % is the percentage of cells found with 
fluorescence above that level under the various 
conditions. 
cells express a GFP reporter under 
the control of Wnt signalling. Under 
standard growth conditions, TLg2 
cells do not differentiate and display 
basal levels of green fluorescence 
(Figure 4, pink; Table 5). When 
these cells are cultured in N2B27 
medium for 3 d, they differentiate, 
there is an activation of the Wnt 
reporter and the median GFP fluor-
escence increases (from 6405 to 
8894 units; Figure 4, blue; Table 5), 
as measured by flow cytometry [51]. 
Inhibitors of the Wnt response will 
lead to a decrease in the percentage 
of cells with fluorescence above this 
value (8894 units). The experiment 
was repeated in the presence of test 
quinazolinones 18c-f, 20c,d, 39 (10 mM) or XAV939 5 (control, 10 mM). 
 
The positive control, XAV939 5, is known to inhibit Wnt signalling in a different model [14,51] 
and this effect was confirmed in our model by diminution to 37% of the proportion of cells 
with GFP fluorescence >8894 units (Figure 4, dark green; Table 5) (compared with 50% for 
no drug and 28% for non-differentiating controls). 8-Methyl-2-(4-trifluoromethylphenyl)quin-
azolin-4-one 18c was shown to be more potent than 5 in this Wnt-inhibition assay, in that it 
reduced the proportion of cells with GFP fluorescence >8894 units to 32% (Figure 4, pale 
green; Table 5), very close to the basal non-differentiating level for these cells. These effects 
are also reflected in the diminution of the median fluorescence values (Table 5). Analogous 
quinazolinones 18d,e, 20c, 39 showed lesser inhibition of the Wnt response in this assay, while 
18f, 20d were effectively inactive. All the test quinazolinones were evaluated for antipro-
liferative activity against HT29 cells (see below and Supplementary Information). Inhibitor 
18c did not display any activity in this MTS cell proliferation assay, consistent with results 
shown using mESCs. 
2.5. Antiproliferative activity 
Compounds 13a-j, 18a-j, 20a-h, 21a-h, 39, 42, 45 and 47 were assessed for their antiprolifer-
ative / cytotoxic effects against HT29 human colon carcinoma cells using an MTS assay. Three 
concentrations of each compound were used (see Supplementary Information). Inhibitors 13j 
and 18j showed inhibition of of the proliferation of HT29 cells in a dose-dependent manner. 
These compounds maintain a 4’-OH substituent but differ at the 8-position (8-H and 8-Me, 
respectively) and display some PARP-1 inhibitory activity (IC50 = 6429 nM and IC50 = 1200 
nM, respectively). Inhibitors 21a (4’-H), 21b (4’-Me), 21d (4’-Cl), 21e (4’-Br), 21h (4’-NH2) 
and 21j (4’-OH) all carry a 8-OH group and are capable of inhibiting the TNKSs and PARP-1. 
Their enzyme-inhibitory activities may complement their observed concentration-dependent 
inhibition of proliferation of HT29 colon cancer cells. The observed correlation between dual 
TNKS-1/-2 and PARP-1 inhibitory activity and inhibition of HT29 cells is also demonstrated 
by 42. We therefore speculate whether dual TNKS and PARP-1 inhibition may be necessary 
for antiproliferative activity against colon cancer cells. Alternatively, it may be that the limited 
Table 5. Summary of the results obtained after flow cytometry 
analysis in TLg2 cells cultured in the indicated culture con-
ditions. E14Tg2A cells are a non-fluorescent control cell line. 
Cell line Culture condition Median 
GFP fluor-
escence 
% cells above the 
median GFP fluor-
escent intensity in 
cells under differen-
tiation (N2B27) 
E14Tg2A 0-3SL 1209 0 
TLg2 0-3SL (standard) 6405 28 
TLg2 
N2B27 
(differentiation) 8894 50 
TLg2 
N2B27 + 
XAV939 5 7424 37 
TLg2 N2B27 + 18c 6650 32 
 
solubility of some analogues in the assay medium masked their antiproliferative effect by not 
allowing a sufficient concentration to be achieved. In general, we observed turbid solutions for 
the 8-Me, 8-OMe and 8-H series of compounds at 100 M (see Supplementary Information). 
The 8-OH group of inhibitors 21a (4’-H), 21b (4’-Me), 21d (4’-Cl), 21e (4’-Br), 21h (4’-NH2) 
and 21j (4’-OH) provides increased aqueous solubility, thus facilitating the observation of 
antiproliferative activity at 100 M. Interestingly, potent and selective inhibitors of TNKSs, 
for example 18c and 5, did not inhibit proliferation of HT29 cells but do inhibit Wnt signalling. 
3. Conclusions 
In this study, the SAR around the 8- and 4’-positions in series of 2-arylquinazolin-4-ones has 
been explored for inhibition of the tankyrases and for activity against the isoforms PARP-1 and 
PARP-2. At the 8-position, a small hydrophobic group (methyl) gave the best potency for 
inhibition of both tankyrases and selectivity in the counter-screen against the isoforms PARP-
1 and PARP-2. Conversely, a polar H-bond donor (8-OH) at this position caused some loss of 
potency against the tankyrases but considerably increased activity against PARP-1. These data 
were rationalised by modelling studies and by comparison of the crystal structures of 
complexes with TNKS-2 and the structure of PARP-1. It was evident that the protein surface 
in the region of space which accommodates the 8-substituent is much more polar in PARP-1 
than it is in the tankyrases. This is the first detailed comparison of the binding sites in these 
related NAD+-binding enzymes. The conclusions are consistent with our previous study of 3-
arylisoquinolin-1-ones, where 5-NH2 (equivalent to the 8-position in the quinazolinones) led 
to increased inhibition of PARP-1 and decreased inhibition of the tankyrases, in comparison 
with the 5-Me analogues. Substitution at the 6- and 7-positions of the quinazolinones is not 
tolerated. We had previously established that the optimum location for a substituent on the 
exocyclic phenyl ring is 4’- [31]. Examination of the surfaces of the binding pockets in this 
region for TNKS-2 and PARP-1 indicated that larger and more hydrophobic substituents would 
be accepted in the tankyrases and this proved to be the case experimentally. Selectivity for 
inhibition of tankyrases is seen for 4’-Cl and 4’-Br, hydrophobic substituents which interact 
well with the hydrophobic surface in tankyrases but not with the tighter hydrophilic surface in 
PARP-1. The 4’-CH2NHCbz unit extends into a tunnel from the cavity towards solvent; this 
tunnel is lined by both hydrophobic and hydrophilic residues. Thus optimum potency and 
selectivity for inhibition of tankyrases by 2-arylquinazolin-4-ones is achieved with 8-methyl 
and 4’-hydrophobic groups. 
8-Methyl-2-(4-trifluoromethylphenyl)quinazolin-4-one 18c is identified by this compre-
hensive study as a highly potent and selective inhibitor of the tankyrases in vitro and in a 
functional cellular assay, with potential for further development as a molecular probe for 
further studies on the roles of the tankyrases. A panel of compounds with differing isoform-
selectivities is now readily available as a tool for cellular studies on the interplay of the 
members of the PARP superfamily. 
4. Experimental 
4.1. Protein crystallography 
Crystal structures of TNKS-2 were used to study the binding modes of the compounds. The 
catalytic domain of TNKS-2 was expressed, purified and crystallised as previously reported 
[39]. Inhibitors were soaked for 48 h into the crystals in a well solution (0.2 M LiSO4, 0.1 M 
Tris-HCl pH 8.5, 24-26% PEG 3350) supplemented with the compound (100 µM) and 250 mM 
NaCl. Before collection of the data, the crystals were briefly soaked in a well solution 
supplemented with 20% glycerol and flash frozen in liquid nitrogen. Data was collected at the 
Diamond Light Source (Didcot, UK) at beamlines I04-1 and I03 and at ESRF (Grenoble, 
France) at beamline ID23-2. Diffraction data were processed and scaled with the XDS package 
[55]. The structures were solved using the Difference Fourier method with the starting phases 
derived from the TNKS-2 structure (PDB accession code 3U9H). REFMAC5 [56] was used 
for refinement and COOT [57] for manual building of the model. Data collection and 
refinement statistics are shown in the Supporting Information. Coordinates and structure 
factors have been deposited into the RCSB Protein Data Bank (http://www.rcsb.org) with the 
following accession codes: 4UHG, 4UI3, 4UI5, 4UI6, 4UI7, 4UI8, 4UFY, 4UFU, 4UI4. 
4.2. Chemical synthesis 
4.2.1. General materials and methods 
Chemical reagents were purchased from Sigma, Aldrich, Fluka, Acros, Lancaster and 
Novabiochem. Dry THF was obtained by distillation over Na / benzophenone. All other 
solvents were purchased from Fisher Scientific. Analytical TLC was performed using silica gel 
60 F254 pre-coated on Al sheets (0.25 mm thickness). Column chromatography was performed 
on silica gel 60 (35-70 mm). Melting points were recorded on a Reichert-Jung Kofler block 
apparatus and are uncorrected. 1H and 13C NMR spectra were recorded using Bruker Advance 
DPX 500 MHz and 400 MHz (1H) instruments. High resolution mass spectra were determined 
using electrospray ionisation (ES) on a Bruker Daltonics MicroTOF instrument and were 
calibrated with Na+ HCO2-. The brine was saturated. Experiments were conducted at ambient 
temperature, unless otherwise stated. Solutions in organic solvents were dried with anhydrous 
MgSO4. Solvents were evaporated under reduced pressure. Details are given below for one 
example of each reaction type; the syntheses and characterisation of analogues are reported in 
the Supplementary Information. The 8-methylquinazolinones 18 were synthesised as reported 
in our preliminary communication.40 
4.2.2. 2-Phenylquinazolin-4-one (13a) 
2-Aminobenzamide 12 (400 mg, 2.9 mmol) was heated with benzaldehyde (310 mg, 2.9 mmol) 
and NaHSO3 (454 mg, 4.3 mmol) at 150C for 3.5 h in N,N-dimethylacetamide (3.5 mL) in an 
open flask. The cooled mixture was poured into water and the precipitate was collected by 
filtration. Chromatography (CH2Cl2  CH2Cl2 / MeOH 97:3) and recrystallisation (EtOAc) 
gave 13a (350 mg, 54%) as white crystals: mp 235-236°C (lit. [58] mp 235-237°C); 1H NMR 
((CD3)2SO)  7.48-7.59 (4 H, m, Ph 2,4,6-H3 + 6-H), 7.72 (1 H, d, J = 8.0 Hz, 8-H), 7.81 (1 H, 
t, J = 8.0 Hz, 7-H), 8.13-8.18 (3 H, m, Ph 3,5-H2 + 5-H), 12.49 (1 H, s, NH); 13C NMR 
((CD3)2SO) (HSQC / HMBC)  120.97 (C-4a), 125.83 (5-C), 126.54 (6-C), 127.44 (Ph 3,5-
C2), 128.56 (Ph 2,6-C2), 131.35 (Ph 4-C), 132.70 (Ph 1-C), 134.54 (7-C), 148.69 (8a-C), 152.27 
(2-C), 162.17 (4-C). 
4.2.3. 2-(4-Trifluoromethylphenyl)quinazolin-4-one (13c) 
Compound 14c (700 mg, 2.3 mmol) was stirred with aq. NaOH (0.5 M, 15 mL) at 60°C for 3.5 
h. The mixture was acidified by addition of aq. HCl (9 M) to pH 2. The precipitate was collected 
by filtration and dried under vacuum to give 13c (620 mg, 94%) as a white solid: mp 305-
308°C (lit. [59] mp 306-308°C); 1H NMR ((CD3)2SO)  7.56 (1 H, t, J = 7.5 Hz, 6-H), 7.78 (1 
H, d, J = 7.5 Hz, 8-H), 7.87 (1 H, m, 7-H), 7.30 (2 H, d, J = 8.0, Ph 3,5-H2), 8.18 (1 H, dd, J = 
8.0, 1.0 Hz, 5-H), 8.37 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 12.75 (1 H, s, NH); 13C NMR ((CD3)2SO) 
(HSQC / HMBC)  121.21 (4a-C), 123.96 (q, J = 270.3 Hz, CF3), 125.50 (q, J = 3.5 Hz, Ph 
3,5-C2), 125.12 (5-C), 127.12 (6-C), 127.69 (8-C), 128.73 (Ph 2,6-C2), 130.98 (q, J = 32.1 Hz, 
Ph 4-C), 134.74 (7-C), 136.61 (Ph 1-C), 148.44 (8a-C), 151.17 (2-C), 162.10 (4-C). 
4.2.4. 2-(4-Hydroxyphenyl)quinazolin-4-one (13j) 
Compound 13i (467 mg, 1.9 mmol) was boiled under reflux with BBr3 in CH2Cl2 (1.0 M, 11 
mL) for 3 h. The solvent was evaporated. The residue was stirred with aq. NaOH (2.5 M, 100 
mL) for 3 h. The mixture was acidified by addition of aq. HCl (9 M) to pH 2. The mixture was 
extracted with ethyl acetate (3  20 mL). Drying and evaporation gave 13j (420 mg, 95%) as a 
white solid: mp 258-261°C (lit. [60] mp 261-263C); 1H NMR ((CD3)2SO)  6.88 (2 H, d, J = 
8.5 Hz, Ph 3,5-H2), 7.46 (1 H, m, 6-H), 7.67 (1 H, d, J = 8.0 Hz, 8-H), 7.80 (1 H, m, 7-H), 8.08 
(2 H, d, J = 8.5 Hz, Ph 2,6-H2), 8.12 (1 H, dd, J = 8.0, 1.5 Hz, 5-H), 10.15 (1 H, s, OH), 12.30 
(1 H, s, NH); 13C NMR ((CD3)2SO) (HSQC / HMBC)  115.34 (Ph 3,5-C2), 120.57 (4a-C), 
123.19 (Ph 1-C), 125.79 (5-C), 125.91 (6-C), 127.18 (8-C), 129.56 (Ph 2,6-C2), 134.50 (7-C), 
149.04 (8a-C), 152.11 (2-C), 160.53 (Ph 4-C), 162.30 (4-C). 
4.2.5. 2-Benzamidobenzamide (14a) 
Dry pyridine (151 mg, 1.2 mmol) was added to 12 (200 mg, 1.47 mmol) in dry THF (4.0 mL), 
followed by benzoyl chloride (228 mg, 1.6 mmol) in dry THF (4.0 mL). The mixture was 
stirred under Ar for 16 h. Evaporation and chromatography (EtOAc / CH2Cl2 2:3) gave 14a 
(351 mg, 99%) as a white solid: mp 233-235°C (lit. [61] mp 234C); 1H NMR ((CD3)2SO)  
7.17-7.19 (1H, m, 5-H), 7.56-7.59 (3 H, m, 4-H + Ar 3,5-H2), 7.63 (1 H, m, Ar 4-H), 7.65 (1 
H, br, s, NHH), 7.89 (1 H, dd, J = 8.0, 1.5 Hz, 6-H), 7.94-7.96 (2 H, m, Ar 2,6-H2), 8.43 (1 H, 
brs, NHH), 8.72 (1 H, dd, J = 8.5, 1.0 Hz, 3-H), 12.96 (1 H, s, NH); 13C ((CD3)2SO) (HSQC / 
HMBC)  119.15 (1-C), 120.00 (3-C), 122.63 (5-C), 126.92 (Ar 2,6-C2), 128.73 (6-C), 128.92 
(Ar 3,5-C2), 132.03 (Ar 4-C), 132.58 (4-C), 140.08 (2-C), 134.60 (Ar 1-C), 164.37 (NHCO), 
171.15 (CONH2). 
4.2.6. 2-Amino-3-methoxybenzamide (16b) 
Compound 15b (3.00 g, 17.9 mmol) in dry DMF (80 mL) was treated with 1,1-
carbonyldiimidazole (3.19 g, 19.7 mmol) at 70C under Ar for 1 h, after which aq. NH3 (35%, 
50 mL) was added dropwise and the mixture was stirred for 16 h. The mixture was cooled to 
20°C and was diluted with EtOAc (100 mL). The mixture was washed twice with water and 
twice with brine. Drying and evaporation gave 16b (2.38 g, 80%) as a white solid: mp 139-
141°C (lit. [40] mp 139-141°C); 1H NMR ((CD3)2SO)  3.77 (3 H, s, Me), 6.23 (2 H, br, Ar-
NH2), 6.44 (1 H, t, J = 8.0 Hz, 5-H), 7.04 (1 H, dd, J = 7.6, 0.8 Hz, 6-H), 7.03 (1 H, brs, 
CONHH), 7.16 (1 H, dd, J = 8.0, 1.2 Hz, 4-H), 7.67 (1 H, brs, CONHH); 13C NMR ((CD3)2SO) 
(HSQC / HMBC)  55.53 (Me), 111.98 (6-C), 113.38 (3-C), 113.64 (5-C), 120.42 (4-C), 140.19 
(1-C), 146.88 (2-C), 171.19 (C=O). 
4.2.7. 2-(4-Aminophenyl)-8-methoxyquinazolin-4-one (20h) 
Compound 20g (100 mg, 0.34 mmol) was stirred with Pd/C (10%, 100 mg) and +NH4 HCO2- 
(212 mg, 3.4 mmol) in MeOH (6 mL) and DMF (6 mL) under Ar for 3 h. The mixture was 
filtered (Celite). Evaporation and chromatography (EtOAc / petroleum ether 4:1) gave 20h (65 
mg, 83%) as a white solid: mp 271-274°C (lit. [47] mp 263-265°C); 1H NMR ((CD3)2SO)  
3.92 (3 H, s, Me), 5.80 (2 H, s, NH2), 6.63 (2 H, dt, J = 8.5, 2.5 Hz, Ar 3,5-H2), 7.29-7.34 (2 
H, m, 6-H + 7-H), 7.64 (1 H, dd, J = 7.5, 2.0 Hz, 5-H), 7.95 (2 H, dt, J = 9.5, 2.5 Hz, Ar 2,6-
H2), 12.09 (1 H, s, NH); 13C NMR ((CD3)2SO) (HSQC / HMBC)  55.97 (OMe), 113.01 (Ar 
3,5-C2), 114.91 (7-C), 116.91 (5-C), 119.11 (Ar 1-C), 121.28 (4a-C), 125.38 (6-C), 129.07 (Ar 
2,6-C2), 140.05 (8a-C), 151.11 (Ar 4-C), 151.98 (2-C), 154.32 (8-C), 162.30 (4-C). 
4.2.8. 2-Amino-4-methylbenzamide (25) 
Compound 22 (3.00 g, 19.8 mmol) in dry DMF (100 mL) under Ar was treated with EDC.HCl 
(4.17 g, 21.8 mmol) and HOBt (3.33 g, 21.8 mmol) for 3 h, after which aq. NH3 (35%, 20 mL) 
was added and the mixture was stirred for 16 h. The evaporation residue, in EtOAc, was washed 
twice with water and with brine. Drying and evaporation gave 25 (2.04 g, 69%) as an off-white 
solid: mp 151-153°C (lit. [62] mp 148°C); 1H NMR ((CD3)2SO)  2.22 (3 H, s, Me), 6.35 (1 
H, dd, J = 8.0, 1.2, 5-H), 6.52 (1 H, d, J = 0.5 Hz, 3-H), 6.57 (2 H, s, NH2), 6.95 (1 H, brs, 
CONHH), 7.48 (1 H, d, J = 8.0 Hz, 6-H), 7.65 (1 H, brs, CONHH); 13C NMR ((CD3)2SO) 
(HSQC / HMBC)  21.03 (Me), 111.14 (1-C), 115.61 (5-C), 116.44 (3-C), 128.77 (6-C), 141.55 
(2-C), 150.31 (4-C), 171.19 (C=O). 
4.2.9. 2-(4-(Phenylmethoxycarbonylaminomethyl)phenyl)benzamide (35) 
Compound 34 (4.00 g, 26.5 mmol) in aq. K2CO3 (1.0 M, 144 mL) was stirred vigorously with 
BnOCOCl (4.52 g, 26.5 mmol) for 16 h. The precipitate was collected by filtration and dried. 
This material was stirred with SOCl2 (10 mL) under Ar for 16 h. The evaporation residue was 
suspended in CH2Cl2 and filtered. Evaporation gave the crude acyl chloride, which was used 
immediately. This acyl chloride in dry THF (70 mL) was stirred with 2-aminobenzamide 12 
(1.96 g, 14.4 mmol), pyridine (1.48 g, 18.7 mmol) and DMAP (0.35 g, 2.88 mmol) under Ar 
for 16 h. The evaporation residue, in EtOAc, was washed twice with water and twice with 
brine. Drying, evaporation and chromatography (EtOAc / CH2Cl2 2:3) gave 35 (5.1 g, 88%) as 
a white solid: mp 180-183°C; 1H NMR ((CD3)2SO)  4.29 (2 H, d, J = 6.0 Hz, CH2), 5.06 (2 
H, s, OCH2), 7.17-7.19 (1 H, m, 4-H), 7.30-7.38 (5 H, m, Cbz Ph 3,5-H2 + Ph 2,6-H2 + Ph 4-
CH2NH), 7.44 (2 H, d, J = 8.0 Hz, Cbz Ph 2,6-H2), 7.57-7.59 (1 H, m, 5-H), 7.86-7.90 (4 H, 
m, Ph 2,6-H2 + CONHH + H-3), 7.94 (1 H, t, J = 7.5 Hz, Cbz Ph 4-H), 8.44 (1 H, s, CONHH), 
8.70 (1 H, d, J = 8.5 Hz, 6-H), 12.95 (1 H, s, 2-NH); 13C NMR ((CD3)2SO) (HMBC / HSQC) 
 43.58 (CH2NH), 65.55 (OCH2), 119.08 (1-C), 120.02 (6-C), 122.64 (4-C), 127.08 (Ph 3,5-
C2), 127.42 (Cbz Ph 2,6-C2), 127.85 (Ph 2,6-C2), 127.89 (3-C), 128.42 (Cbz 3,5-C2), 128.79 
(Cbz Ph 4-C), 132.66 (5-C), 133.24 (Ph 1-C), 137.13 (Cbz Ph 1-C), 140.18 (2-C), 144.08 (Ph 
4-C), 156.47 (Cbz NHCO), 164.26 (NHCO), 171.20 (CONH2); MS (ES) m/z 426.1437 [M + 
Na]+ (C23H21N3NaO4 requires 426.1430). 
4.2.10. 2-(4-(Phenylmethoxycarbonylaminomethyl)phenyl)quinazolin-4-one (38) 
Compound 35 (100 mg, 0.25 mmol) was stirred with aq. K2CO3 (1.0 M, 50 mL) at 100°C for 
16 h. The cooled reaction mixture was acidified to pH~1. The precipitate was collected by 
filtration. Chromatography (EtOAc / petroleum ether 3:2) gave 38 (90 mg, 94%) as a white 
solid: mp 244-248°C; 1H NMR ((CD3)2SO)  4.30 (2 H, d, J = 6.5 Hz, Ar 4-CCH2), 5.07 (2 H, 
s, Cbz CH2), 7.32-7.38 (5 H, m, Cbz Ph-H5), 7.42 (2 H, d, J = 8.5 Hz, Ar 3,5-H2), 7.52 (1 H, 
m, 6-H), 7.74 (1 H, d, J = 8.0 Hz, 8-H), 7.84 (1 H, m, 7-H), 7.94 (1 H, t, J = 6.0 Hz, CH2NH), 
8.13-8.16 (3H, m, Ar 2,6-H2 + 5-H), 12.55 (NH); 13C ((CD3)2SO) (HMBC / HSQC)  44.25 
(Ar 4-CCH2), 66.17 (Cbz CH2), 121.62 (4a-C), 126.54 (5-C), 127.19 (6-C), 127.76 (Ar 3,5-
C2), 128.13 (8-C), 128.47 (Ar 2,6-C2 + Cbz 2,6-C2), 128.52 (Cbz 4-C), 129.06 (Cbz 3,5-H2), 
131.96 (Ar 1-C), 135.28 (7-C), 137.80 (Cbz 1-C), 144.05 (Ar 4-C), 149.52 (8a-C), 152.84 (2-
C), 157.13 (Cbz-CO), 163.10 (4-C); MS (ES) m/z 408.1317 [M + Na]+ (C23H19N3NaO3 requires 
408.1324]. 
4.2.11. 2-(4-(Aminomethylphenyl)quinazolin-4-one hydrobromide (41) 
Compound 38 (0.15 g, 0.39 mmol) was stirred with HBr in AcOH (33%, 1.5 mL) for 16 h. 
Evaporation gave 41 (0.13 g, 92%) as a white solid: mp 277-285°C; 1H NMR (CD3OD)  4.34 
(2 H, s, CH2), 7.76 (1 H, m, 6-H), 7.85 (2 H, d, J = 8.0 Hz, Ar 3,5-H2), 7.90 (1 H, d, J = 8.5 
Hz, 8-H), 8.03 (1 H, m, 7-H), 8.14 (2 H, d, J = 8.0 Hz, Ar 2,6-H2), 8.36 (1 H, dd, J = 8.0, 1.0 
Hz, 5-H); 13C NMR (CD3OD) (HMBC / HSQC)  43.72 (CH2), 121.30 (4a-C), 122.36 (8-C), 
128.32 (5-C), 129.28 (Ar 1-C), 130.23 (6-C), 130.83 (Ar 2,6-C2), 131.00 (Ar 3,5-C2), 137.54 
(7-C), 140.85 (Ar 4-C), 141.58 (8a-C), 158.58 (2-C), 161.40 (4-C); HRMS (ES) m/z 252.1140 
[M + H]+ (C15H14N3O requires 252.1137]. 
4.2.12. 2-Phenylthieno[3,4-d]pyrimidin-4-one (45) 
Compound 44 (580 mg, 2.8 mmol) was stirred with K2CO3 (1.17 g, 8.5 mmol), CuBr (40 mg, 
0.28 mmol) and BnNH2 (610 mg, 5.7 mmol) at 125°C in an open flask for 16 h in DMSO (28 
mL). The mixture was diluted with EtOAc (30 mL) and was washed twice with water and twice 
with brine. Drying, evaporation, chromatography (CH2Cl2  EtOAc / CH2Cl2 1:5) and 
recrystallisation (CH2Cl2) gave 45 (102 mg, 16%) as a yellow solid: mp 280-283°C (lit. [46] 
275-277°C); 1H NMR ((CD3)2SO)  7.50-7.56 (3 H, m, Ar 3,4,5-H3), 7.86 (1 H, d, J = 3.5 Hz, 
7-H), 8.10 (2 H, m, Ph 2,6-H2), 8.51 (1 H, d, J = 3.5 Hz, 5-H), 11.93 (1 H, s, NH); 13C NMR 
((CD3)2SO) (HSQC / HMBC)  118.32 (7-C), 125.01 (4a-C), 127.61 (Ph 2,6-C2), 127.89 (5-
C), 128.50 (Ph 3,5-C2), 131.04 (Ph 4-C), 132.91 (Ph 1-C), 148.72 (7a-C), 150.86 (2-C), 158.91 
(4-C). 
4.3. Enzyme assays 
Test compounds were assayed for inhibition of tankyrase-1, tankyrase-2, PARP-1 and PARP-
2 activity as described previously [31, 33, 40]. 
4.4. Mouse embryonic stem cell culture and Wnt signalling reporter assay 
The cell lines used in this study were E14Tg2A (a mouse embryonic stem cell (mESC) line) 
and TLg2 (derived from E14Tg2A and harboring a Wnt-responsive element driving eGFP) 
[51,54]. The activity of the test compounds was assessed as described previously [51]. Briefly, 
TLg2 cells were plated on gelatin at low density (4  104 cells per well in a 6-well plate) in 
either serum + LIF (standard culture conditions) or in the presence of N2B27 (differentiating 
conditions) in the absence (untreated) or presence (treated) of test compound (10 M). The 
medium was refreshed daily and the Wnt activity was assessed by flow cytometry using a LSR 
Fortessa cytometer (BD Bioscience). Live single cells were selected on forward and side scatter 
area, side scatter width vs. area and DAPI exclusion (405 laser and 450/50 filter set). Expression 
of eGFP was assessed using the 488 laser and 530/30 filter set. Data were analyzed and 
presented using Flowjo software (TreeStar). No test compound was toxic during the 3 d of 
treatment. 
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Figure 1. Structures of 1-11, reported inhibitors of tankyrases. 
 
Figure 2. Conformations of aroylanthranilamides 48 and 2-arylquinazolinones 49 in solution. 
 
Figure 3. Crystal structures of Panel A 13b, Panel B 13c, Panel C 20b, Panel D 20c, Panel E 
21b, Panel F 21c, Panel G 18b, Panel H 18c, Panel I 38 bound to TNKS-2. Overlay of 38 
onto PARP-1 (panel J). Key residues are in purple and key H-bond interactions are shown as 
dashed lines. 
 
Figure 4. Flow-cytometric analysis of TLg2 cells (and E14Tg2A control cells) grown under 
the indicated culture conditions. The black line indicates the median GFP fluorescence 
intensity of TLg2 cells cultured for 3 d in the presence of N2B27 medium and % is the 
percentage of cells found with fluorescence above that level under the various conditions. 
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Reagents and conditions: i, ArCHO, NaHCO3, AcNMe2, 150°C, open flask; ii, +NH4HCO2-, 
Pd/C, MeOH, DMF; iii, BBr3, CH2Cl2, reflux, then NaOH; iv, ArCOCl, pyridine, dry THF. 
 
Scheme 2. Synthesis of 2-arylquinazolin-4-ones 18,20,21 with various 4’- and 8-substituents. 
Reagents and conditions: i, CDI or EDC, aq. NH3, DMF; ii, ArCOCl, pyridine, dry THF; iii, 
aq. NaOH (0.5 M), 60 °C; iv, +NH4HCO2-, Pd/C, MeOH, DMF; v, BBr3, CH2Cl2, reflux, then 
NaOH. 
 
Scheme 3. Synthesis of 6- and 7-substituted 2-arylquinazolin-4-ones 31-33. Reagents and 
conditions: i, CDI, aq. NH3; ii, ArCOCl, pyridine, dry THF; iii, aq. NaOH (0.5 M). 
 
Scheme 4. Synthesis of 2-arylquinazolin-4-ones 38-43 with extensions at the 4’-position. 
Reagents and conditions: i, CbzCl, aq. K2CO3; ii, SOCl2, iii, 12 or 16a or 27, pyridine, dry 
THF; iv, aq. K2CO3 (1.0 M), 100°C; v, HBr, AcOH. 
 
Scheme 5. Synthesis of thienopyrimidinone 45 and ferrocenylquinazolin-4-one 47. Reagents 
and conditions: i, K2CO3, CuBr, BnNH2, 125°C, DMSO, open flask; ii, ferrocenecarbonyl 
chloride, pyridine, dry THF; iii, aq. NaOH (0.5 M), 100°C. 
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